Organisation paid for research Program year 2024 Source: CMS Open Payments

Central Dermatology PC

Neither a doctor nor a teaching hospital

Research payments

$516,522

109 payments

Through program year 2024, Central Dermatology PC is reported as receiving $516,522 in research payments, across 109 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $294 1
2023 Research $35,089 6
2022 Research $28,438 12
2021 Research $37,556 16
2020 Research $214,812 33
2019 Research $200,332 41

Breakdown

Who paid Research payments · program years 2019–2024
  1. Eli Lilly and Company $281,645 59 payments
  2. Amgen Inc. $119,962 2 payments
  3. Janssen Research & Development, LLC $81,122 38 payments
  4. AbbVie, Inc. $27,893 8 payments
  5. Pfizer Inc. $5,000 1 payment
  6. Ucb SA $900 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. Efficacy/Safety study of Apremilast in subjects with Mild-to-moderate Plaque Psoriasis (PSOR-022) $119,962 2 payments
  2. A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $63,871 7 payments
  3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis $56,904 5 payments
  4. A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa $51,066 14 payments
  5. A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) $26,547 7 payments
  6. A Phase 1 Randomized Double-Blind Placebo-Controlled Study to Investigate Safety Tolerability and Pharmacokinetics With Single Intravenous Ascending Doses and Single and Multiple Subcutaneous Doses of Ly3848575 in Healthy Participants Including Firs $25,640 1 payment
  7. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $24,310 3 payments
  8. Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis $22,835 13 payments
  9. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $21,148 4 payments
  10. Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-To-Severe Plaque Psoriasis $13,453 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record